Table 1. Patient characteristics.
| n=51 | |
|---|---|
| Age (median) | 73 (42–88) |
| Sex ratio M/W | 28/23 |
| Number of AZA cycles (range) | 7 (1–42) |
| Hemoglobin, g/dl | |
| <8 | 10 (20%) |
| 8–10 | 20 (39%) |
| >10 | 21 (41%) |
| Absolute neutrophils count, x103/l | |
| <0.8 | 32 (63%) |
| >0.8 | 19 (37%) |
| Platelet count, × 103/l | |
| <50 | 22 (43%) |
| 50–100 | 18 (35%) |
| >100 | 11 (22%) |
| BM blasts | |
| <10% | 0 (0%) |
| >10% | 51 (100%) |
| >20% | 31 (61%) |
| Cytogenetic group | |
| Very good | 0 |
| Good | 23 (45%) |
| Intermediate | 9 (18%) |
| Poor | 8 (15%) |
| Very poor | 11 (22%) |
| IPSS-R classification | |
| Very low | 0 |
| Low | 1 (2%) |
| Intermediate | 4 (8%) |
| High | 25 (49%) |
| Very high | 21 (41%) |
Abbreviations: AZA, azacitidine; BM, bone marrow; IPSS-R, revised International Prognostic Scoring system.